Proteasome– tag –
-
Gan & Lee’s First-in-Class AR PROTAC GLR2037 Receives NMPA Approval to Initiate Clinical Trials for Advanced Prostate Cancer
flcube.com China Overview Gan & Lee Pharmaceuticals announced that China's National Medical Products Administration (NMPA) has approved its first-in-class androgen receptor (AR) PROTAC, GLR2037, for clinical trials. This novel therap... -
First PROTAC Therapy for Breast Cancer Approved, Opening New Avenues for Precision Medicine in Advanced, Metastatic Disease with Specific Mutations
Nature Medicine Journal (Facebook) International Overview A PROTAC therapy for breast cancer has received medical approval, pioneering a new era of precision medicine for patients with advanced or metastatic breast cancer harboring speci... -
Protein Accumulation Mechanism is Key to PROTAC Efficacy, Unlocking New Strategies for Refractory Cancers
News-Medical UK Overview Researchers have discovered that the mechanism by which cancer-driving proteins accumulate within tumors significantly influences the efficacy of PROTAC drugs. The study demonstrated that PROTACs are more effecti... -
BRD4-Targeting PROTAC Nanoassemblies Dramatically Enhance FLASH Radiotherapy, Achieving Robust Tumor Suppression
PMC USA Overview New research reveals that BRD4-targeting PROTAC nanoassemblies (APF) significantly amplify the anti-tumor efficacy of ultra-high dose rate FLASH radiotherapy (FLASH-RT). By efficiently delivering the BRD4 degrader ARV-77... -
Clinical Landscape of Targeted Protein Degradation Explored, Molecular Glues Show Faster Progress with Nanomedicine Delivery Strategies
MDPI Unknown Overview A new review analyzes the clinical landscape of targeted protein degradation (TPD), focusing on PROTACs and molecular glue degraders, noting that the smaller molecular size of molecular glues may enable faster clini... -
Molecular Glue Degraders Expand Druggable Proteome in Cancer Research: Simple Structure Boosts CNS Delivery Potential
Facebook USA Overview Molecular glue degraders, small molecules that stabilize interactions between otherwise non-interacting proteins, are expanding the 'druggable' proteome in cancer research through targeted protein degradation. Unlik... -
PROTACs vs. Molecular Glues: Comparing Targeted Protein Degraders for Size and Permeability in Drug Selection
Drug Target Review UK Overview PROTACs and molecular glues represent two distinct strategies for targeted protein degradation, each with unique advantages and challenges. PROTACs are bifunctional molecules that recruit an E3 ligase to a ... -
FDA Grants Accelerated Approval to BMS’s Zenbexus for Multiple Myeloma in Combination with Daratumumab
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's (BMS) Zenbexus (iberdomide), a novel CELMoD (cereblon E3 ligase modulator), for the treatment of multiple myelom... -
Dana-Farber Unveils Platform to Unlock ‘Undruggable’ Targets with Novel Molecular Glue Degraders, Discovering First Metabolically Activated Agents
Facebook (reposting Dana-Farber Cancer Institute news) USA Overview Researchers at Dana-Farber Cancer Institute have developed an innovative, scalable platform for systematically discovering molecular glue degraders (MGDs) that target pr... -
FDA Grants Accelerated Approval to BMS’s CELMoD Zenbexus in Quadruple Therapy for Relapsed/Refractory Multiple Myeloma
Drugs.com, FDA.gov USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's cereblon E3 ligase modulating agent (CELMoD) Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexametha...
